Indian shares slide as US growth concerns, foreign sell-off weigh

India’s benchmark indexes closed lower on Monday, extending their losing streak to a fifth straight session, as concerns over slowing growth in the U.S. and persistent selling by foreign investors rattled domestic investors.

The Nifty 50 fell 1.06% to 22,553.35, while the BSE Sensex lost 1.14% to 74,454.41, their lowest levels in nearly eight months.

Domestic equities have been under selling pressure for most of February. The blue-chip Nifty 50 has fallen in 15 out of 17 trading sessions, losing over 4%, on consistent foreign outflows, uncertainty about U.S. tariff policies, and concerns over slowing domestic growth.

The session’s drop came on the back of data on Friday that showed U.S. business activity tumbled in February, pressuring emerging markets such as India, which has companies earning a significant amount of revenue from clients in the U.S.

Ten of the 13 major sectors fell on the day, with heavyweight financials and information technology falling 0.8% and 2.7%, respectively, which analysts said was due to a sell-off from foreign portfolio investors (FPI) with substantial exposure to these sectors.

The two indexes combined accounted for nearly two-thirds of the Nifty 50’s losses on the day.

Indian equity benchmarks log weekly losses on US tariff risks

The excitement around China has further intensified the FPI sell-off, two fund managers said.

“China is getting a lot of attention due to attractive valuations and excitement around their tech sector,” said Anand Vardarajan, business head at Tata Asset Management.

The broader and more domestically focussed mid-cap and small-cap indexes also fell 0.9% and 1%, respectively.

The indexes are down 18% and 21%, respectively, from their record-high levels on concerns over costlier valuations and weak earnings.

Bucking the trend, auto stocks rose 0.2%, following a sharp fall in the previous week on looming tariff worries.

Glenmark Pharma advanced 1.8% after settling antitrust and consumer protection lawsuits related to a generic cholesterol drug.